Clinical Trial: Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07683026) titled 'Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo' on June 24.

Brief Summary: The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years.

Participants will:

* Take golimumab or placebo injections monthly for the duration of the study or until they are diagnosed with either stage 2 or stage 3 Type 1 Diabetes

* Visit a study clinic every 6 months for Oral Glucose Tolerance Tests (OGTTs) and other tests until the end of the study

Study Start Date: ...